Differential (Click to cross reference) aphasia, logopenic, progressive aphasia, progressive, non-fluent aphasia, progressive, primary atypical axonal degeneration axonal injury biologic markers bone marrow transplantation cardiac arrest cardiac arrest and resuscitation cerebral cortical atrophy cerebrospinal fluid cerebrospinal fluid, abnormal chemotherapy, CNS treatment and complications with complications differential diagnosis disability, neurological efficacy facial nerve palsy frexalimab hydrocephalus, exvacuo leukemia monoclonal antibodies MRI, abnormal MRI, contrast enhanced MRI, volumetry multiple sclerosis multiple sclerosis, treatment of neuroaxonal degeneration neurofilament light chain protein neurofilaments neurologic disease neurologic disease, diagnoses of neurotoxic neurotoxicity, acute Parkinson disease Parkinson disease, atypical Parkinson disease, diagnosis Parkinson disease, differential diagnosis of Parkinsonism syndrome prognosis review article safety stem cell transplantation

Showing articles 0 to 7 of 7 Inhibition of CD40L with Frexalimab in Multiple Sclerosis NEJM 390:589-600, 662, Vermersch,P.,et al, 2024 Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest JAMA Neurol 76:64-71, Moseby-Knappe, M.,et al, 2019 Serum NFL discriminates Parkinson Disease from Atypical Parkinsonisms Neurol 92:e1479-e1486, Marques, T.M.,et al, 2019 Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology JAMA Neurol 76:1035-1048, Bridel, C.,et al, 2019 Blood-based NfL - A biomarker for differential diagnosis of parkinsonian disorder Neurol 88:930-937,922, Hansson, O.,et al, 2017 Neurofilament as a Blood Marker for Diagnosis and Monitoring of Primary Progressive Aphasias Neurol 88:961-969, Steinacker, P.,et al, 2017 Evidence for Acute Neurotoxicity After Chemotherapy Ann Neurol 68:806-815, Petzold,A.,et al, 2010 Showing articles 0 to 7 of 7